医药价格和招采信用评价制度的法律定位及实践价值  

Legal Positioning and Practical Value of Medical Price and Bidding Credit Evaluation System

作　　者：孙阳 宗欣 SUN Yang;ZONG Xin(Beijing Medical Centralized Purchasing Service Center,Beijing,China 100161;School of Pharmaceutical Sciences,Capital Medical University,Beijing,China 100069)

机构地区：[1]北京市医药集中采购服务中心,北京100161 [2]首都医科大学药学院,北京100069

出　　处：《中国药业》2023年第15期1-5,共5页China Pharmaceuticals

摘　　要：目的探讨医药价格和招采信用评价的法律实质,完善该评价制度。方法比较医药价格和招采信用评价与社会信用评价,对医药价格和招采信用评价的法律实质进行定位。通过国家医疗保障局网站,收集2021年1月至2022年10月我国医药价格和招采信用评价案件相关数据,对各地医药企业失信行为进行评价。结果医药价格和招采信用评价与社会信用评价在评价范围、适用领域、基础法律关系上有明显区别,前者的法律实质是基于医药集中采购机构、医药企业及医疗机构间的多方民事法律关系。全国有9个省/直辖市/自治区的15家企业被评价为“严重”“特别严重”失信;案由以医药商业贿赂为主,占86.67%(13/15),其涉案金额范围为45万元~325万元;涉案品类涵盖药品和医用耗材,其中药品包括化学药和中药饮片,抗菌药物注射剂失信情况较突出。结论医药价格和招采信用评价对医药集中采购市场运行具有重要意义,建议加强医药价格和招采信用评价制度法律依据和评价规则研究,拓宽医药价格和招采失信事项目录失信行为案源来源,将医药价格和招采信用承诺内容纳入平台协议管理,加强医药价格和招标采购领域立法,以完善医药价格和招采信用评价制度。Objective To investigate the legal essence of medical price and bidding credit evaluation system,and to improve the evaluation system.Methods The difference between the medical price and bidding credit evaluation and social credit evaluation was compared,and the legal essence of medical price and bidding credit evaluation was identified.Through the website of the National Healthcare Security Administration(NHSA),the data related to the cases of medical price and bidding credit evaluation in China from January 2021 to October 2022 were collected to evaluate the credit-lacking of pharmaceutical enterprises in various regions.Results There were significant differences in the evaluation scope,applicable fields,and basic legal relationships between the medical price and bidding credit evaluation and social credit evaluation.The legal essence of the former was based on a multi-party civil legal relationship among medical centralized purchasing institutions,pharmaceutical enterprises and medical institutions.Fifteen credit-lacking enterprises in nine provinces municipality directly under the central government/autonomous region in China have been evaluated"serious"and"particularly serious"credit-lacking rating.The main cause of the cases was medical commercial bribery,accounting for 86.67%(13/15),and the amount involved ranged from CNY 0.45 million to CNY 3.25 million.The categories involved in the cases included drugs and medical consumables,and drugs included chemicals and traditional Chinese medicine decoction pieces.The situation of credit-lacking in antibiotic injections was prominent.Conclusion The medical price and bidding credit evaluation is of great significance for the operation of the centralized pharmaceutical procurement market.It is recommended to strengthen the research on the legal basis and evaluation rules of the medical price and bidding credit evaluation system,broaden the sources of credit-lacking behavior in the catalog of medical price and bidding credit,incorporate the content of medical price a

关 键 词：医药价格和招采信用评价制度 社会信用评价 医药集中采购 

分 类 号：R951[医药卫生—药学]